Pilot Study to Investigate a Cannabinoid Derived Drug in Dogs

Tetra Bio-Pharma and Panag Pharma Advance their Veterinary Drug Pipeline 

ORLEANS, Ontario, Nov. 15, 2018 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) (TSX VENTURE: TBP) (OTCQB: TBPMF) and Panag Pharma Inc. (“Panag”) today announced the submission of a clinical research application to the Veterinary Drugs Directorate at Health Canada. This first of a kind veterinary study will examine the use of a cannabinoid-based drug to treat ocular pain and inflammation in canines. The pilot study will be led by veterinary ocular care specialists. 

“Several companies are marketing cannabis-based treatments for aliments in companion animals, but there is a major gap

...read more at https://globenewswire.com/news-release/2018/11/15/1652088/0/en/Pilot-Study-to-Investigate-a-Cannabinoid-Derived-Drug-in-Dogs.html